BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 12376811)

  • 1. Effective removal of methotrexate by high-flux hemodialysis.
    Saland JM; Leavey PJ; Bash RO; Hansch E; Arbus GS; Quigley R
    Pediatr Nephrol; 2002 Oct; 17(10):825-9. PubMed ID: 12376811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma.
    Widemann BC; Balis FM; Kempf-Bielack B; Bielack S; Pratt CB; Ferrari S; Bacci G; Craft AW; Adamson PC
    Cancer; 2004 May; 100(10):2222-32. PubMed ID: 15139068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucarpidase (carboxypeptidase g2) intervention in adult and elderly cancer patients with renal dysfunction and delayed methotrexate elimination after high-dose methotrexate therapy.
    Schwartz S; Borner K; Müller K; Martus P; Fischer L; Korfel A; Auton T; Thiel E
    Oncologist; 2007 Nov; 12(11):1299-308. PubMed ID: 18055849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of methotrexate intoxication with various modalities of continuous extracorporeal therapy and glucarpidase.
    Vilay AM; Mueller BA; Haines H; Alten JA; Askenazi DJ
    Pharmacotherapy; 2010 Jan; 30(1):111. PubMed ID: 20030480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Carboxypeptidase-G2 administration after high-dose methotrexate. Treatment and drug interactions].
    Cózar Olmo JA; Martínez Colmenero C; Peláez Pleguezuelos I; Leiva Gea I; López García AB; de la Cruz Moreno J
    An Pediatr (Barc); 2009 Sep; 71(3):230-4. PubMed ID: 19617010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early recognition of renal toxicity of high-dose methotrexate therapy: a case report.
    Nowicki TS; Bjornard K; Kudlowitz D; Sandoval C; Jayabose S
    J Pediatr Hematol Oncol; 2008 Dec; 30(12):950-2. PubMed ID: 19131789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of high-dose methotrexate therapy (HD-MTX) on glomerular and tubular kidney function.
    Hempel L; Misselwitz J; Fleck C; Kentouche K; Leder C; Appenroth D; Rost M; Zintl F
    Med Pediatr Oncol; 2003 Jun; 40(6):348-54. PubMed ID: 12692801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carboxypeptidase-G2 rescue in a patient with high dose methotrexate-induced nephrotoxicity.
    Widemann BC; Hetherington ML; Murphy RF; Balis FM; Adamson PC
    Cancer; 1995 Aug; 76(3):521-6. PubMed ID: 8625136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucarpidase rescue in a patient with high-dose methotrexate-induced nephrotoxicity.
    Tuffaha HW; Al Omar S
    J Oncol Pharm Pract; 2011 Jun; 17(2):136-40. PubMed ID: 19833686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toxic encephalopathy and delayed MTX clearance after high-dose methotrexate therapy in a child homozygous for the MTHFR C677T polymorphism.
    Müller J; Kralovánszky J; Adleff V; Pap E; Németh K; Komlósi V; Kovács G
    Anticancer Res; 2008; 28(5B):3051-4. PubMed ID: 19031955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delayed elimination of high-dose methotrexate and use of carboxypeptidase G2 in pediatric patients during treatment for acute lymphoblastic leukemia.
    Svahn T; Mellgren K; Harila-Saari A; Åsberg A; Kanerva J; Jónsson Ó; Vaitkeviciene G; Stamm Mikkelssen T; Schmiegelow K; Heldrup J
    Pediatr Blood Cancer; 2017 Jul; 64(7):. PubMed ID: 27966809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Difficulty measuring methotrexate in a patient with high-dose methotrexate-induced nephrotoxicity.
    Al-Turkmani MR; Law T; Narla A; Kellogg MD
    Clin Chem; 2010 Dec; 56(12):1792-4. PubMed ID: 21119035
    [No Abstract]   [Full Text] [Related]  

  • 13. Population pharmacokinetics of high-dose methotrexate after intravenous administration in pediatric patients with osteosarcoma.
    Colom H; Farré R; Soy D; Peraire C; Cendros JM; Pardo N; Torrent M; Domenech J; Mangues MA
    Ther Drug Monit; 2009 Feb; 31(1):76-85. PubMed ID: 19077931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Understanding and managing methotrexate nephrotoxicity.
    Widemann BC; Adamson PC
    Oncologist; 2006 Jun; 11(6):694-703. PubMed ID: 16794248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of plasma exchange in methotrexate removal in a patient with osteosarcoma and acute renal insufficiency.
    Cecyn KZ; Lee J; Oguro T; Petrilli AS; Bordin JO
    Am J Hematol; 2003 Mar; 72(3):209-11. PubMed ID: 12605394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severe methotrexate toxicity precipitated by intravenous radiographic contrast.
    Harned TM; Mascarenhas L
    J Pediatr Hematol Oncol; 2007 Jul; 29(7):496-9. PubMed ID: 17609630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A device for rapid elevation of plasma methotrexate (MTX) concentration and its maintenance in high-dose MTX therapy].
    Miyauchi Y; Mii Y; Morishita T; Miura S; Honoki K; Aoki M; Kido A; Tamai S; Hino M; Nomura Y; Nakanishi E
    Gan To Kagaku Ryoho; 1996 Apr; 23(5):595-9. PubMed ID: 8678518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucarpidase for the treatment of life-threatening methotrexate overdose.
    Tuffaha HW; Al Omar S
    Drugs Today (Barc); 2012 Nov; 48(11):705-11. PubMed ID: 23170306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carboxypeptidase-G2, thymidine, and leucovorin rescue in cancer patients with methotrexate-induced renal dysfunction.
    Widemann BC; Balis FM; Murphy RF; Sorensen JM; Montello MJ; O'Brien M; Adamson PC
    J Clin Oncol; 1997 May; 15(5):2125-34. PubMed ID: 9164227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methotrexate nephrotoxicity: Novel treatment, new approach.
    Iqbal S; Armaghani A; Aiyer R; Kazory A
    J Oncol Pharm Pract; 2013 Dec; 19(4):373-6. PubMed ID: 24255083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.